

FIG. 10




FIG.





FIG. 3A

G TAT GGA ACA GGA TGT TTC TTA CTA TGT $\frac{A}{G}$ AT ACA GGC CAT AAG


SEQ ID NO: 16 **SEQ ID NO: 13 SEQ ID NO: 14** SEQ 1D NO: 15 VEPAMVKNTYGTGCFMLMIGNELKYSQIINLLTTVAMQLEN SEQID NO: 18 DRPGLLKCTYGTGAFLVMTGQTVTRSQHRLLSTVAMTQTN SEQID NO: 19 SEQ ID NO: 17 **SEQ ID NO: 12 SEQ ID NO: 10** SEQ ID NO: 11 SEQ ID NO: 8 SEQ ID NO: 6 SEQ ID NO: 7 SEQ ID NO: 9 TEPGMVKNTYGTGCEVI.MNI GDKPTLSKIINI.I.TTVAMQI.E.N FEPGMVKNTYGTGSFIVMNTGEEPQLSKNNLLTTTGY--GI Y K PGAAKC'T Y GT GC FT.I. WITGTKK LJ SQIIGALT''T LAFW FPII VEPGQAKNI'YGTGCFLLMI'I'GDKAVKSI'IIGLLI'I'TLAC--GP VHAGQAKNITYGITGCEMLIHTGNKATTSKNGLLITTACNAKG FQ1GQAKNTYGTGCFLL(DTGHKCVFSDHGLL)TTVAYKLGR FQDGQAKNTYGTGCFLLANTGHKCVFSEIIGLLTTTVAYKLGR FQDGQAKNTYGTGCFLLCNTGHKCVFSEHGLLTTVAYKLGR VKEGMAKNTYGTGCFMI.MYTGEKAVKSENGI.ITTTC--GP FEKGMTKNTYGTGAFTVMNTGEEPQLSDNDLLTTTGY--GL FEEGMGKNTYGTGCFMLMNTGFKATKSEHGLLTTTAM--GL FQ I GQAKNTYGTGCFLLCNTGHKCVFS DHG I.I.TTVAYK LGR 270 GK N288D Mutant glpk_mycpn glpk_mycge glpk_human glpk_mouse glpk_syny3 glpk_pseae glpk_haeln glpk_bacsu glpk_entfa glpk_entca glpk_yeast glpk_ecoli glpk_rat

FIG. 3B



Zh Giur pse (mmol/L)

FIG. 4A



poly: A/G

location:13th base of exon 3

ATGCCTTCTTTTGTCAAAGATGGGTGGAACA [A/G] GACCCTAAGGAAATTCTACAT

TCTGTCT SEQ ID NO: 1

CAA vs CAG ==> silent

poly: A/C

location:17th base of intron 8

TAATGGTAAAAAACAAACAAA [A/C] AAACAAAAAACACACCAAAAAAACCAA

SEQ ID NO: 2

poly: A/G

location: 29th base of exon 10

TTCATTCTCCCTTCAACCATAGGTATGGAACAGGATGTTTCTTACTATGT [A/G] AT

ACAGGCCATAAGGTEGGTTTTTAATAAAAATGATTAAGTCA SEQ ID NO: 3

AAT vs GAT ==> N to D

poly: G/T

location: 22nd base of intron 12

GAAATTGGTGAGTGTTCTAACAAAAG [G/T]TTAGAAAATCTGAAAAATGACACA

TTTCA SEQ ID NO: 4

SEQ ID NO: 5

GGTTCAGCGGACGCGCGCGCCTCGGTCTCTGGACTCGTCACCTGCCCCTCCCCCTCCCGCC GCCGTCACCCAGGAAACCGGCCGCAATCGCCGGCCGACCTGAAGCTGGTTTCATGGCAGCCT TTTTTGGTGAGCCCGGGGTGACATGTGAAGAGGCGCTGAGC

TGTAAAACGACGGCCAGTCATCCTTGATATCTGCCTGCATTTTTACATTAATATTACAATAT CTTTTTCAGGTTTTCAATTCAAAAACAGCTGAACTACTTAGTCATCATCAAGTAGAAATAAA ACAAGAGTTCCCAAGAGAAGGGTATGTTTCCTAATTTAATATGTAAAGACACATTATGTTTG TTAGTCCATCTCACCCAACTTGCCC

CAATGCCTTCTTTTGTCAAAGATGGGTGGAACA [A/G] GACCCTAAGGAAATTCTACATTCT GTCTATGAGTGTATAGAGAAAACATGTGAGAAACTTGGACAGCTCAATATTGATATTTCCAA CATAAAAGGTATTTTAGTAGAATATTTTACCCACA

TGTAAAACGACGGCCAGTTGAGAGCTGTTTTCCTGAAGTAGTTCCTACTTGTTAAATTTTTG ${\tt ACTTCCTTCTGTTTAACTTTCTCTTTAAAGCTATTGGTGTCAGCAACCAGAGGGAAACCACT}$ GTAGTCTGGGACAAGATAACTGGAGAGCCTCTCTACAATGCTGTGGGTAAGCTGTCATGCAT GGATGTCAAATGTAGGGCCTTTCTTCACATTGCAA

 ${\tt TGTAAAACGACGGCCAGTTCCTTGATAGTGATTTCAGTAAGTTCTTATTTTTTAAATGAAG}$ CGTTGAGAGTCTTAGTAAAAGAATTCCAGGAAATAATAACTTTGTCAAGGTAAGAATTCTT ${\tt CAGAAGTATACTATAAGAATGTTTCTTTTTTAAAAAAAGTTTGCAGATTTCACTAGAAAGA}$ AGCATCTTATGGTACAATAGTTATTTGATACAATTTATAGAATCTTTTTCCCCGGATAATTGA GGCC

 ${\tt TGTAAAACGACGGCCAGTTTCTTTTGTTTGGTGGTTTTGTTTTAAACTGTTACACTTTTCAT}$ CAGTGCAGTGAAACTTCGTTGGCTCCTTGACAATGTGAGAAAAGTTCAAAAGGCCGTTGAAG ${\tt AAAAACGAGCTCTTTTTGGGACTATTGATTCATGGCTTATTTGGGTATGTTTAAATATAATG}$ GATATATGGAGAATTTTTTCAGAAATTTTTTCTAGACTGCCTATTGTTTCTACTAGC AGGTCAGACTTTTTAATTAGCA

Exon 7:

TGTAAAACGACGGCCAGTTGTGCTCTGCTGATTATGACCCTTAACAATATGTAAATTAAATT GCCAATAAGTACAAATTTAACCTGATTTTTTTACTCTGCCTAGAGTTTGACAGGAGGAGTCA ATGGAGGTGTCCACTGTACAGATGTAACAAATGCAAGTAGGACTATGCTTTTCAACATTCAT TCTTTGGAATGGGATAAACAACTCTGCGAGTAAGTTCTGTTTTGCTCTAAATATAGTTTTCC CAATACACTACCTATTTATAACCGAAATCTTAATATTTTCAGATGTCAGTGGAGCA

TGTAAAACGACGGCCAGTACAGTGTTAAATACCCAATCTTCTTGTTTTTCAGATTTTTTGGA ATTCCAATGGAAATTCTTCCAAATGTCCGGAGTTCTTCTGAGATCTATGGCCTAATGGTAAA TAATAATTAAAGTTTTTTTTTATTACAAAACAAGTTTACTATTCATAATTCAAAAGTCAACTGT GTTATGTTTTGTGACTTAAAAACTTTACAGTCCTTTTTACAATGG

Exons 9A and 9B

AAAGCTGGGGCCTTGGAAGGTGTGCCAATATCTGGGGTAAGTTTCATCACCAAGTGTCTCCC CATCCCCACCCTTCCCCATGTTATGGCTTTCCTCCTCTTAGTTCATCAGTGTGCCTCTTTTT AAACTAGGGAAAACAAGTAAAAGTTGCAAAATTGGANNNNTCTTGTTCTTACATGTCATACT GTGGGCCATTGAGAATCTTTTGAATAAATTAATTTTAACTCTCCCTTCCCATACCTATTATC TTACATATTAACAAATGGTATTAACAAATGGGGAAAATGGCCAAATGGAGAAAATGCAAGGA AGAAAGTTAATACTATTGTATTAGTCAGTGTTCTTTATTGTCATTTATACTTTCAGTGTTTA GGGGACCAGTCTGCTGCATTGGTGGGACAAATGTGCTTCCAGATTGGACAAGCCAAAAATAC ATAAGGAAAAGCTTTTGAAGTTCATCCAGGATGAAAATCAATAGCTTAATAGCTCCAATATG CATATATACACTTTTTACCATTTTTTTATATCTTTAAATAAAATACAAAA TGCCATATATATGCACACTGATGAAGCTTATAAAGACCTAAATTTGTAGGCTGGGCGCGG

Exons 10 and 11:

TTATTTGCTTTCAATAAAATTGTCTTCTATTCATTCTCCCTTCAACCATAGGTATGGAACAG GATGTTTCTTACTATGT [A/G] ATACAGGCCATAAGGTTGGTTTTTTAAATTAAAAAATTGA TTTAAAAGTCTAAGTTCATCTAAATAATGCTTGAACATAATTTACTATTAAACAACTTTTAG TCTTTAGCTTTACTTAATCTTTATCAGGGTTTAATTTAGAGCTCAATACAAAATTTGAATC GTTCTAATAAGAACCATTTTAGACTCTTTGAATTTTATATGTGTGTTTTTAATTGTGCTGGG GGGAAATCTAGACTGAGACCTCATCAAATTCTTAATGCAAATCTAATTTGAAACAAGGAATA ATTTTCTGATCATGGCCTTCTCACCACAGTGGCTTACAAACTTGGCAGAGACAAACCAGTAT ATTATGCTTTGGAAGTAAGTTCTTTTTAATCAATATGGATAATATGACAAACATTCAAAGCT AATAAAAATCACAGAGTTTTCTAACACTTTTCTGGTAAATCTTAATACAGAGGACTCAAAAA GTTCTGCTTTCTTGGCATTTGATTGAGTTGAAGGAACCTGAAACTGATCTGGGTGTCAGGAC TCACAGGAGACCTTGATTAGATTGGTTCCTCAGTTCTTATGCCAATTAATCATGTCACCTTA TGCTCCAGTGTTCCAAAGAGAACCCTGGGCACAAATAGGCAGAACAACTCTCTTCACTTGTC CCACTTATCACTGGAAACATTTGTTTCAAACATTTTTGTATGTTATAGTAGGAATATGCCAG CCTAAGCCTATA

Excn 12:

TTTTATTAGTGACTTAGATAAAACTATGTTTGTATTAGAAGACCTAGTTTACATATTTGTCG GAGTCTCAAAATGGAAACTGAATTCTGTCCATCTGATTGTGTCATACACAGAATATGCTCAA TGTAGCTATAGCTGGTGCTGTTATTCGCTGGCTAAGAGACAATCTTGGAATTATAAAGACCT CAGAAGAAATTGGTGAGTGTTCTAACAAAAG [G/T] TTAGAAAATCTGAAAAATGACACA TTTCAGTATTTTATCTCTGCAAAGTAAATATCGATGCTTTGCCCCCAAATGTGAT

Exon 13:

CCAGTTGTGTGTTTTTGTTTTTGTTTTAATGTTAGAAAAACTTGCTAAAGAAGTAGG TACTTCTTATGGCTGCTACTTCGTCCCAGCATTTTCGGGGTAATATGCACCTTATTGGGAGC CCAGCGCAAGAGGGTAAGTATTGAAAATATGGAGTGCTTTTGGGGATCTTGATTTAT

Exons 14 and 15:

TGTAAAACGACGGCCAGTTGATTATGTCCAATTTTCTCTTCCTGGACATTTCTGTCTACCAA ATTTGACCTTTTCATATTTGAGATATTTCAAATTGATTGGTTTATATCATTCTAATCTGAAA TGCTTTTGCTGCATTAGAAGCTGTTTGTTTCCAAACTCGAGAGGTAACAAATATGGGCCTGT TTTCTTGTACTTAGTTCACTTTTATCACTCTTAAGTTATATGTTAACACCCGAGATTTATTC AGTACTGAAAATGTAGTTAATCAAATATTAAGGCTGCCTAAATACTAATCTAAATATAAGCA GGGTTTTCCCCCTTTTTCCAGCTGTCATTACCTTCTAAGTTCCTGTTCCCTGTCAGGCACTG GGAAATTTATGGTTGTGGGGAGGCTGAGTGGCACACATTAGGCAAAGGAAACAGCACAAACA TAGGCATCaAGGCAGAAAAACAGGGTGCAAAATAGAGTTGTATAGCTTAGCTGAATATCAAG GTGAATGCAGAGGTGTAGTGAGAAAAAGGTTGGCTGTGACCAGATCAAAGAGGGCTTAGAA GACCAGAATAAGAAGTCTCAATTTATTCCATAGGCTCTTGGAAGCTCTTGAGAGTTTCTGAG TGGAGGATTGCCATTTTCAGAGATGTTACTATGAAATAGATTTATAACATTAATTGCACTGG TTTATTTAAGATTTTGGATGCCATGAATCGAGACTGTGGAATTCCACTCAGTCATTTGCAGG TAGATGGAGGAATGACCAGCAACAAAATTCTTATGCAGCTACAAGCAGACATTCTGTATATA CCAGTAGGTTAGTAAGTCTTCATTCCTTTAAACTCCCAGAGTAATGTTTCTTGTGGAATAAC TAGTTCTTTGGG

TGTAAAACGACGGCCAGTTCCCAGAGTAATGTTTCTTGTGGAATAACTAGTTCTTTGGGCAT Exon 16: ATGTAACCACAAAGATATTGATGGAACTCTCTCTCCTCAGTGAAGCCCTCAATGCCCGAAAC CACTGCACTGGGTGCGGCTATGGCGGCAGGGGCTGCAGAAGGAGTCGGCGTATGGAGTCTCG AACCCGAGGATTTGTCTGCCGTCACGATGGAGCGGTTTGAACCTCAGATTAATGCGGAGGGT ACATTTAAAGAATGAAATGTTCAGTGATATACTGTGAAAACGACCTTAGTGCACGGGAGTTT TGTTTTTCTGTTTAGTTAAAAGTTAAGGAACCAAGTAAAATAGTAAATGTTATCATTGCAGA TTCGGCTGCCAAGCATATTGGGCTTTACTGAATAAATGTGAATGAGAGAAATCGTTGCTTAT CAAAAGAACTTCTAAAATCACTTTTTAAAAATCATT

Exon 17:

TGTAAAACGACGGCCAGTAGCCCTACTGCAGTTTAATGTGTCAATAATTTGTCAAGAATGTT GAGTGATCATAAGTATGGTACTAAGAACATCTCAGCAAACTACCTTTCGTTATGTGTTTTTT CTACCTTCTAATTCTAGAAAGTGAAATTCGTTATTCTACATGGAAGAAAGCTGTGATGAAGT CAATGGGTTGGGTTACAACTCAATCTCCAGAAAGTGGTAAAAATGTTTTTTGTTTATTATTGT CACATTTTCTTAGTATATTAAATAGTTATTTAAGTATCTAGGCATTTACACATAGCCAGGCT GCTCTGAAGAAAGCATTATCATATGTCCAGAGATTCTGACATTTTGAAAACACTTTAAAGT TCTAAACACAAAATGTAAATTATCAGGTGT

TGTAAAACGACGGCCAGTTGGTTTGGTTTGCTTGACTGGAATCTCTTCTGCTTGGATGACCA CAGGTGACCCTAGTATCTTCTGTAGTCTGCCCTTGGGCTTTTTTATAGTGAGTAGCATGGTA ATGTTAATCGGAGCAAGGTACATCTCAGGTTAGTTACTCTTTAAATTAGACAACTCTATTAG TTAGCTTTAATGTTTTCGTGTATAACTTAGCAGAAATTTTTCAGTGTTTTTCATTCTTCTG CAGTTAGAAGTAAGAACTGTGACTCTGCTTACCCTTTTTAAATTTTTAATGTGATGACTTCT TTAAGAGGGACTACATTCTGCTGTCAGCTGCAGCAATAAGCAAAAGTGAAAATACTAATATT TAAATGACAGGACTTTCAGACTGACTGCTGAAAGTTAAAGTATACTT

AAAATTACTGGCTTAAATGGAAATGATGCTTCTTATTCTGTATGTTCCCATGAAAGTGAAAC TTAAAAAAAATTCATGATTAGGGTTTCATGAAAAGGCCTTGTTTCTATGAAAATTGAGAC ${\tt AGGTTGCATCTCTAAGCTAAAAGATGGGCTATGTGTCTAGAGTCTTAGACTTCTAAAATG}$ CATGTGGTCACTATATGTAGGTTATCTCTTCGGTGACATACACTGCAATTTGAGAGGGCTGG AAATTGTTTGCCTTGGTAAACGATTAGCAACAGTGGCAATATTTGTTAATTTTGGAATTGGC CCTGTTTGTTGCATTTTAATTGTGAGGCATGATTTAGAAATCATATGGACTTTCTAGCTTAA TAAATGATTGAATCATCTGCATTGCTTTAACTCCTGAATTGTATGCATGTATTATTGACATA TATGGTTTTTGTTCCCCATTTCAGGTATTCCATAAAACCTACCAACTCATGGATTCCCAAGA TGTGAGCTTTTTACATAATGAAAGAACCCAGCAATTCTGTCTCTTAATGCAATGACACTATT CATAGACTTTGATTTTATTATAAGCCACTTGCTGCATGACCCTCCAAGTAGACCTGTGGCT TAAACATCCACAGTTAAGGTTGGGCCAGCTACCTTTGGGGCTGACCCCCTCCATTGCCATAA CATCCTGCTCCATTCCCTCTAAGATGTAGGAAGAATTCGGATCCTTACCATTGGAATCTTCC ATCGAACATACTCAAACACTTTTGGACCAGGATTTGAGTCTCTGCATGACATATACTTGATT AAAAGGTTATTACTAACCTGTTAAAAATCAGCAGCTCTTTGCTTTTAAGAGACACCCTAAAA GTCTTCTTTTCTACATAGTTGAAGACAGCAACATCTTCACTGAATGTTTGAATAGAAACCTC TACTAAATTATTAAAATAGACATTTAGTGTTCTCACAGCTTGGATATTTTTCTGAAAAGTTA TTTGCCAAAACTGAAATCCTTCAGATGTTTTCCATGGTCCCACTAATTATAATGACTTTCTG CTTTGTATGTATAACATACATGCCTATATATTTTATACACTGAGGGAGCCCATTTATAAATA AAGAGCACATTATATTCAGAAGGTTCTAACAGGG

TABLE 1

Characteristics of carriers of the N288D GK gene mutation and of their unaffected relatives

Men		Women -				
	N288D	Unaffected relatives	. p	N288D carriers	Unaffected relatives	P
N	18	18		14	14	
Age (years)	46,4±14,2	42,0±18,8	0.32	44,9 = 13,5	43,7=17,8	0.87
Unco rrected triglyceride (mmol/L) ⁽¹⁾	6,26=1,13	2,05±0,54	<0,0001	2,84=1,20	1,30=0,65	0.0002
Giyceral (mmoi/L)	3,99±0,71	0,10±0,04	<0.0001	0,54=0.14	0,10=0,02	<0,0001
Corrected trigiyceride (mmol/L) ⁽¹⁾	2,27±0,75	1,95 ± 0,53	<0,0001	2,31=1,22	1,19 _ 0,67	0.03
Free farry acid (mmoVL)	0,77=0,22	0,25±0,25	10.0.	1,2 9± 0,35	0,76=0,17	0.0004
Fasting glucose	5,2 <u>=</u> 0,74	4,3=0,31	0.13	5,0 ± 0,7	4,6=0.3	0.10
2h giucose following OGTT	7,9 = 3,1	5,8±1,6	0.02	7,0 ±6 .!	5,0 =2 .1	0.04
(mmol/L) Fasting insulin (mU/L)(1)	13,3=14,0	15,1=14,8	0.62	12,2=13.1	9,0 <u>=</u> 3,4	0.60
Waist girth (cm)	97,7 ±3 ,3	88,1=12,3	0.01	88,5 ± 3,3	79,3=5,3	0.03
Body mass index (kg/m²)	27,9 =4 ,1	24,9=3,9	0.03	28,1=5,5	23,1=2,3	0.001
% total body fat	27,1±7,2	22,9 ± 7.5	0.01	. 46,3=3.1	33,9 = 11,3	0.00

⁽¹⁾ geometric mean, a value after log transformation

TABLE 2

Fasting plasma glycerol concentration (mmoVL) in the initial conort of 1056 individ :als, by risk factor of glucose intolerance and diabetes mellitus

ву п				
	<u> </u>		Giycerol	
· .		No.	geometric mean±SD	р
Gender				
men .		717	0.065 ± 0.081	<0.0001
. women	- premenopaused	137	0.071 ± 0.093	20,0001
	- menopaused	202	0.099 ± 0.085	
Age (Y)		486	0.071 ± 0.082	
	< < 0	408	0.076 = 0.106	0.0015
• .	50 - 60		0.083 = 0.053	
	> 6 0	165		
Fasting glucese (mmoVL)	 · <5.2	449	0.063 ± 0.080	
	5.2 - 5.9	336	0.070 ± 0.090	<0,0001
•	6,0 - 6.9	271	0.090 ± 0.100	
Fasting insulin (UI)				0.02
racing instance (+)	5</td <td>637</td> <td>0.067 = 0.082</td> <td>0.02</td>	637	0.067 = 0.082	0.02
	. ≥15	419	0.086 ± 0.101	
2 hours giucose (mmoVL)			0.06z = 0.071	
	<7,3	572	0.081 ± 0.101	<0.0001
	7,3 - 11,0	283	0.102 = 0.110	
	□11.1	201	0.102 = 0.110	
Triglycaride (mmol/L)		189	0.057 = 0.062	<0.0001
	≤ 2.2	567	0.082 ± 0.103	**
	>2.3	201	515-2 =	
Free fatty, acid (mmol/L)	< 0,6	589	0,0 66 ± 0.054	<0.000
	€ 0,6	467	0.111 ± 0.112	
•	0,0			-
Body mass index (kg/m2)	. ≤27	423	0.060 ± 0.087	<0.000
•	>27	623	0.079 ± 0.097	

TABLE 3. Multivariate analysis of the relationships of fasting pla maglycerol concentration with impaired glucose tolerance (2h glucose 7,8-11,0 mmol/L following a 75 g oral load) before and after adjustment for covariates identified in

	Model 1	Model 2	Model 3	Model 4
Glyceroi (log)				0.7′
B	1.75	1.62	1.46	2.4 i
Odds ratio	5.76	5.42	4.33	0.0
р	<0,0001	<0,0001	1000,0>	9.5
Triglyceride (log)		0.54	0.35	0.13
ß		1.75	1.42	1.11
Odds ratio		0.02	0.11	0.63
p		0.02		
Body mass index (kg/m²)		•	0.10	0.03
В			1.10	1.05
Odás rado	•		<0,0001	0.C l
₽ .				•
Fasting insulin (log)				0.57
ß				1.31
Odds ratio			•	0.19
P				
Fasting glucose (mmol/L	-)			1.13
ß				2.t 5
Odds ratio				<0,0101
þ				
Free fatty acid (log)				i.t 2
B				4.; 3
Odds ratio	•			O.C)7
p				

Odds ratios are expressed as the increase in the risk of 2h glucose •7.3 m nol/L foilowing a 75 g oral charge, associated with a 1-SD increase in the variables studied. B denotes the standardized estimate which is the parameter estimate of each variable in the multivariate logistic model. All models included 44 and gender as covariates. Otherwise, only the variables included in each model are shown Subjects with severe hypervivorrollemia due to the N788D mutation in the